CREB3L2 and hepatocellular carcinoma: The findings revealed that HCC cells with relatively high levels of CREB3L2 demonstrated marked resistance to lenvatinib, while downregulation of CREB3L2 notably enhanced the sensitivity to lenvatinib (Fig. 7A–C and Supplementary Fig. S5A–C).